R&D Strategies for T Cell Engager Drugs
From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...
Continue Reading
From hematologic malignancies to solid tumors Introduction: Amid a surge of advancements in immunotherapy, T cell engager (TCE) therapy has...
Continue Reading
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
Continue Reading
Overview of AAV Gene Therapy: Evolution and Current Landscape Adeno-associated virus (AAV) is a non-enveloped, replication-defective single-stranded DNA virus belonging...
Continue Reading
Evidence suggests that type 2 diabetes mellitus (T2DM) is associated with cognitive dysfunction and an increased risk of developing neurocognitive...
Continue Reading
T-cell engagers (TCEs) are a class of bispecific antibodies that simultaneously bind tumor cells and T cells, activating T cells...
Continue Reading
Mechanisms, Recent Progress, and Animal Models Radionuclide drug conjugates (RDCs), a novel class of precision tumor-targeting therapeutic and diagnostic agents,...
Continue Reading
Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...
Continue Reading
Current preclinical murine models of heart failure with preserved ejection fraction (HFpEF) require prolonged modeling periods, posing significant challenges for...
Continue Reading
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
Continue Reading